Kristina Sjöblom Nygren
Director/Board Member at INFANT BACTERIAL THERAPEUTICS AB
Net worth: 748 $ as of 2024-03-30
Profile
Kristina Sjöblom Nygren is an Independent Director at Infant Bacterial Therapeutics AB since 2018.
She was previously a Group Director-Development at Astrazeneca AG from 2007 to 2008 and a Medical Director at Pfizer AG from 1998 to 2003.
She also served as the Chief Medical Officer, EVP & Head-Development at Santhera Pharmaceuticals Holding AG from 2017 to 2020.
Additionally, she was a Vice President & Head-Clinical Development at Swedish Orphan Biovitrum AB.
Dr. Sjöblom Nygren holds a doctorate degree from Karolinska Institutet.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2022-12-30 | 100 ( 0.00% ) | 748 $ | 2024-03-30 |
Kristina Sjöblom Nygren active positions
| Companies | Position | Start |
|---|---|---|
| INFANT BACTERIAL THERAPEUTICS AB | Director/Board Member | 2018-05-14 |
Former positions of Kristina Sjöblom Nygren
| Companies | Position | End |
|---|---|---|
| SANTHERA PHARMACEUTICALS HOLDING AG | Chief Tech/Sci/R&D Officer | 2020-12-30 |
| Astrazeneca AG | Corporate Officer/Principal | 2007-12-31 |
| Pfizer AG | Chief Tech/Sci/R&D Officer | 2002-12-31 |
| SWEDISH ORPHAN BIOVITRUM AB | Corporate Officer/Principal | - |
Training of Kristina Sjöblom Nygren
| Karolinska Institutet | Doctorate Degree |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| SANTHERA PHARMACEUTICALS HOLDING AG | Health Technology |
| SWEDISH ORPHAN BIOVITRUM AB | Health Technology |
| Private companies | 3 |
|---|---|
| Astrazeneca AG | |
| Pfizer AG | |
| Infant Bacterial Therapeutics AB |
- Stock Market
- Insiders
- Kristina Sjöblom Nygren
